Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05902533 · ClinicalTrials.gov registry record · Phase 2
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
A Phase 2 study of Anal Cancer, sponsored by University of Cincinnati.
- Active
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 3
- Study locations
NCT05902533: Active Phase 2 study of Anal Cancer, sponsored by University of Cincinnati.
NCT05902533 is a Phase 2 study of Anal Cancer that is active but no longer recruiting, run by University of Cincinnati. The registered enrollment target is 33 participants, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05902533, a Phase 2 study of Anal Cancer, is active but no longer recruiting, sponsored by University of Cincinnati.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
Primary Outcome
Toxicity Index for all GI, GU, Dermatologic, and Hematologic CTCAE events from treatment initiation through 90 days post treatment. In patients treated with IMRT enrolled to NRG/RTOG 0529, the mean GI/GU/Derm/Hem TI was 3.858 (SD=0.892) assessed during this time period with standard nodal dose using a simultaneous integrated boost technique. Thirty-three patients will allow an effect size of 0.4 with 80% power and one-sided alpha of 0.05. This effect size is larger than the difference in toxicit
Conditions Studied
Interventions
- DRUG Capecitabine
- RADIATION Radiation (reduced elective nodal dose (30.6 Gy)
- DRUG Mitomycin c
Study Locations (3)
Ohio
- University of Cincinnati Medical Center - Cincinnati
- Ohio State University Medical Center - Columbus
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2029-08-14 |
| Phase | Phase 2 |
What the registry record for NCT05902533 still lists
NCT05902533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Capecitabine is the first listed.
NCT05902533 reports a single indexed study location in Ohio, Vermont.
Frequently Asked Questions
What is clinical trial NCT05902533 about?
NCT05902533 is a clinical study titled "REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation". To determine the efficacy of reduced elective nodal radiation in anal cancer patients undergoing chemoradiation in reducing toxicity compared to standard nodal irradiation.
What is the current status of trial NCT05902533?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2023-08-14. Estimated completion is 2029-08-14.
What conditions does trial NCT05902533 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT05902533?
The interventions under investigation include: Capecitabine (DRUG), Radiation (reduced elective nodal dose (30.6 Gy) (RADIATION), Mitomycin c (DRUG).
Who is sponsoring clinical trial NCT05902533?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05902533 being conducted?
This trial has 3 study locations across Ohio, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05902533's enrollment target sits among peer trials
33 13th of 19 higher than 7 of 19 other Anal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
RECRUITING · Phase 2
-
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
COMPLETED · Phase 2
-
Pembrolizumab in Metastatic Anal Cancer
COMPLETED · Phase 2
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI